Original Biotech’s Facility Successfully Audited by FDA

Original Biotech, a leading biotechnology firm, its facility has successfully undergone an audit by the U.S. Food and Drug Administration (FDA). The audit, conducted on April 24, 2024, evaluated the company's compliance with international standards and regulations concerning product safety, quality, and manufacturing processes.

The FDA's audit is a critical component in ensuring that biotechnology firms meet stringent requirements for the development and production of health-related products. This successful audit underscores Original Biotech’s facility’s commitment to maintaining high standards in its operations and its dedication to delivering safe and effective products to the global market.

"We are proud to have met the rigorous standards set by the FDA," said Bruce Wen, spokesperson for Original Biotech. "This audit reaffirms our dedication to quality and safety in all our processes, and it strengthens our position as a trusted leader in the biotechnology industry."

Original Biotech specializes in the research, development, and production of innovative biotechnological products. With this successful FDA audit, the company continues to expand its footprint in international markets, providing top-tier products that meet global standards.